Filter posts

Deal Structures: More Options for Companies

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal …

Ten Years of Therapeutic Venture Capital

What therapeutic areas have received the most funding in private drug companies over the last …

Forbes Asks: Should Economists Perform Surgery and Doctors Conduct Economic Policy?

Over at Forbes, University of Chicago economist Tomas Philipson has an insightful post analyzing several …

Announcing the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey

Click here for the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey. Your investment plans and …

Exclusive FDA Survey Webinar

BIO is conducting an exciting new survey designed to measure FDA/Sponsor Interactions During Drug Development.  …

The Eyes Have It According to Recent VC Funding Patterns

A recent Wall Street Journal analysis of venture capital investment trends since 1999 reveals which …

Back to School: Consider a STEM Career

With school resuming for many throughout the country this week, one question that may be …

Goodbye, For Now, to our Summer Intern

Summer is winding down. Over the next few weeks, student will be returning to America’s …

Biotech Stocks: Perspective in a Bull Market

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong …

Biobased Companies Take A Closer Look At Sustainability

BIO and its member companies are constantly working together to help shift the world’s reliance …